 |
17 Diseases |  |
1 Trial |
|
1 Trial |  |
24 News |  |
- || Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ? (clinicaltrials.gov) - Oct 15, 2024
P1, N=12, Active, not recruiting, Sponsor: GC Biopharma Corp
Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
- Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
TWO-YEAR SAFETY AND EFFICACY EXTENSION STUDY OF GC1111 IN MPS-II PATIENTS TREATED WITH GC1111 OR IDURSULFASE DURING PHASE 3 STUDY (Poster Room | Level 0) - Jul 30, 2024 - Abstract #SSIEM2024SSIEM_451;
Long-term treatment of GC1111 for 2 years and switched treatment from idursulfase both showed sustained efficacy and tolerable safety. Therefore, GC1111 could be a promising alternative treatment option to idursulfase as ERT for MPS-II.
- || Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
Trial completion: A Study of GC1111 in Hunter Syndrom Patients (clinicaltrials.gov) - Apr 16, 2024
P3, N=32, Completed, Sponsor: Green Cross Corporation
Therefore, GC1111 could be a promising alternative treatment option to idursulfase as ERT for MPS-II. Unknown status --> Completed
- | Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ? (clinicaltrials.gov) - Apr 11, 2024
P1, N=12, Recruiting, Sponsor: GC Biopharma Corp
Unknown status --> Completed Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Jun 2026
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
COMBINED ALLOGENEIC BONE MARROW TRANSPLANTATION AND INTRACEREBROVENTRICULAR ENZYME REPLACEMENT THERAPY FOR PATIENTS WITH NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II (Room 253) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1002;
Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Jun 2026 Recently, IDS-beta (Hunterase
- || Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
Enrollment open, Trial initiation date: A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ? (clinicaltrials.gov) - Oct 17, 2022
P1, N=12, Recruiting, Sponsor: GC Biopharma Corp
Recently, IDS-beta (Hunterase Not yet recruiting --> Recruiting | Initiation date: Jun 2022 --> Sep 2022
- | Hunterase (recombinant human iduronate-2-sulfatase) / GC Pharma
Journal: Impact of ERT and follow-up of 17 patients from the same family with a mild form of MPS II. (Pubmed Central) - Aug 31, 2022
Not yet recruiting --> Recruiting | Initiation date: Jun 2022 --> Sep 2022 Here, the authors report the variable progress of the disease with and without ERT in a large Brazilian family with a slowly progressive form of MPS II, harboring the same missense variant in the IDS gene.
- || Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
New P1 trial: A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ? (clinicaltrials.gov) - Jun 15, 2022
P1, N=12, Not yet recruiting, Sponsor: GC Biopharma Corp
- |||| Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
New P3 trial: A Study of GC1111 in Hunter Syndrom Patients (clinicaltrials.gov) - Apr 18, 2019
P3, N=34, Recruiting, Sponsor: Green Cross Corporation
- | Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
New P2 trial: Study of Idursulfase-beta (GC1111) in Hunter Syndrome (clinicaltrials.gov) - Jan 26, 2016
P2, N=20, Not yet recruiting, Sponsor: Green Cross Corporation
- Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
Enrollment open: The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients (clinicaltrials.gov) - Jun 22, 2014
P=N/A, N=34, Recruiting, Sponsor: Green Cross Corporation
Here, the authors report the variable progress of the disease with and without ERT in a large Brazilian family with a slowly progressive form of MPS II, harboring the same missense variant in the IDS gene. Not yet recruiting --> Recruiting
- Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
Trial completion: GC1111: Safety and Efficacy of Hunterase (clinicaltrials.gov) - Nov 5, 2013
P3, N=6, Completed, Sponsor: Green Cross Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
New P3 trial: GC1111: Safety and Efficacy of Hunterase (clinicaltrials.gov) - Jul 18, 2012
P3, N=6, Completed, Sponsor: Green Cross Corporation
- | Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
Trial completion: To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients (clinicaltrials.gov) - Feb 11, 2012
P1/2, N=31, Completed, Sponsor: Green Cross Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed